

IL-6 antagonists of the invention which are derived from the
IL-6 receptor molecule are as follows:

B2 Trp-Arg-Lys- (D) Arg-Phe-AlaC3-Leu-Arg- (D) Tyr-AlaN3-NH₂
designated herein as PTR-5045 (SEQ ID NO:25);
(D) Lys-Arg- (D) Leu- (D) Arg- (D) Phe-AlaC3- (D) Leu-Arg- (D) Tyr-AlaN3-
NH₂ designated herein as PTR-5041 (SEQ ID NO:18);
(D) Phe-Arg- (D) Leu- (D) Arg- (D) Phe-AlaC3-Leu- (D) Tyr-AlaN3-NH₂
designated herein as PTR-5043 (SEQ ID NO:4)."

Please replace the title on page 37, line 33, starting
with "Example 1. Detailed synthesis of PTR 5045 (SEQ ID
NO:25)"

B3 Please replace the paragraph on page 39, line 7, starting
with "Peptides were added to B16.F10.9 melanoma cells in the
presence of 200 ng/ml IL-6 and 125 ng/ml sIL-6R. Incubation
for three days. (Peptide concentration was calculated for
average molecular weight of 1500 Da. Sequence of control
peptides: PTR 5049 (L Form of SEQ ID NO:25): Trp-Arg-Lys-
(D) Arg-Phe-AlaC3-Leu-Arg-Tyr-AlaN3-NH₂. The results described
in figure 2 show that PTR 5045 (SEQ ID NO:25) and PTR 5041
(SEQ ID NO:18) fully block IL-6 activity at concentration of
about 250 nM while PTR 5049 (L Form of SEQ ID NO:25) and PTR
4041 (SEQ ID NO:33) are not active."

B4 Please replace the paragraph on page 40, line 31,
starting with "PTR 5045 (SEQ ID NO:75) was tested in this
model in compare to the non-relevant control peptide PTR 4041
(SEQ ID NO:33) (Lys-GlyC2-Leu-Ile-Gln-Leu-Phe-GlyN3-Lys-Lys-
NH₂). The results are summarized in the following table 3."

B5 Please replace the title on page 45, line 1, starting
with "Table 4: Summary of synthesis and bioactivity of
certain preferred PTRs (SEQ IDs NO:34 to NO:45)."

B6 Please replace the title on page 46, line 1, starting
with "Table 5: Certain preferred backbone cyclic peptide
analogs capable of inhibiting IL-6 derived from either IL-6,
IL-6R (SEQ IDs NO:46 to NO:76) or gp130."